Biotechnology Companies By Enterprise Value

Current Valuation
Current ValuationEfficiencyMarket RiskExp Return
1ABBV AbbVie Inc
361 B
 0.38 
 0.89 
 0.34 
2AMGN Amgen Inc
202.37 B
 0.02 
 1.39 
 0.03 
3GILD Gilead Sciences
108.28 B
(0.06)
 1.83 
(0.11)
4REGN Regeneron Pharmaceuticals
100.28 B
 0.25 
 1.11 
 0.27 
5VRTX Vertex Pharmaceuticals
99.88 B
 0.16 
 2.03 
 0.32 
6HLN Haleon Plc
48.65 B
 0.02 
 1.45 
 0.03 
7BIIB Biogen Inc
37.82 B
(0.05)
 1.70 
(0.08)
8MRNA Moderna
27.88 B
 0.08 
 3.94 
 0.31 
9ARGX Argenx NV ADR
21.71 B
(0.06)
 3.86 
(0.23)
10GRFS Grifols SA ADR
19.07 B
(0.07)
 5.42 
(0.41)
11ALNY Alnylam Pharmaceuticals
18.41 B
(0.05)
 2.61 
(0.14)
12BMRN Biomarin Pharmaceutical
16.7 B
(0.08)
 1.53 
(0.12)
13BGNE BeiGene
16.4 B
(0.03)
 3.30 
(0.10)
14GMAB Genmab AS
14.03 B
(0.11)
 2.10 
(0.23)
15SRPT Sarepta Therapeutics
12.5 B
 0.22 
 3.26 
 0.71 
16NBIX Neurocrine Biosciences
12.37 B
 0.13 
 1.63 
 0.20 
17EXAS EXACT Sciences
12 B
(0.07)
 2.65 
(0.19)
18LEGN Legend BiotechCorp
11.25 B
 0.04 
 2.56 
 0.10 
19KRTX Karuna Therapeutics
10.79 B
 0.15 
 6.26 
 0.92 
20INCY Incyte
9.85 B
 0.06 
 2.03 
 0.12 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents. Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.